-
-
-
-
-
-
-
FDA tightens requirements for COVID vaccine, adding trials for healthy adults
-
-
-
-
-
-
-
Jefferies Downgrades Moderna (MRNA) to Hold
-
-
-
-
-
-
-
Jefferies on Moderna (MRNA): 'Phase III Flu/Covid Combo looks good - could be on market in 2025'
-
-
-
-
-
-
-
Moderna (MRNA) PT Raised to $125 at Jefferies ahead of RSV launch and CMV data
-
-
-
-
-
-
-
Moderna flu shot succeeds in late-stage study
-
-
-
-
-
-
-
Jefferies Upgrades Moderna (MRNA) to Buy
-
-
-
-
-
-
-
Moderna asks investors to wait for full data on flu vaccine amid selloff
-
72,358 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

